RxDoctor Payments Data

Herbert Insel, MD

Cardiovascular Disease · New York, NYNPI 1356427652

Payments from drug & device makers

$3,929in general payments, 2019–2025

Across 173 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$910
  • Esperion Therapeutics, Inc.$419
  • Novo Nordisk$390
  • Boehringer Ingelheim$379
  • Johnson & Johnson$334
  • Amarin Pharma, Inc.$333
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,929100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,929 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$114,968
Medicare patients
245
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$117,994
XareltoRivaroxaban29$46,998
OzempicSemaglutide30$38,611
FarxigaDapagliflozin Propanediol26$32,126
Repatha SyringeEvolocumab19$31,281
Repatha SureclickEvolocumab21$20,518
JardianceEmpagliflozin16$18,797
MounjaroTirzepatide13$13,640
Ezetimibe201$7,248
Rosuvastatin Calcium215$4,189
Atorvastatin Calcium369$3,493
Metoprolol Succinate154$2,536
Olmesartan Medoxomil78$1,947
Amlodipine Besylate145$1,283
Amlodipine-ValsartanAmlodipine Besylate/Valsartan16$1,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$117,99493 claims
Johnson & JohnsonXarelto$334$46,99829 claims
Novo NordiskOzempic$390$38,61130 claims
AstraZenecaFarxiga$66$32,12626 claims
Boehringer IngelheimJardiance$379$18,79716 claims
Lilly USA, LLCMounjaro$205$13,64013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →